



Curriculum Vitae

Surname: Kim

First name: Jaihwan

Affiliation and official address :

Division of Gastroenterology,

Department of Internal Medicine,

Seoul National University Bundang Hospital,

Seoul National University College of Medicine

82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea 13620

Phone, Fax number and E-mail address:

Tel: +82-31-787-7075

Fax: +82-31-787-4290

Mobile: +82-10-8937-5645

drjaihwan@snu.ac.kr, drjaihwan@snuh.org

Education

- ✓ Medical Graduate (M.D.), College of Medicine, Seoul National University, Korea, 2002
- ✓ Master of Medicine, Dept. of Internal Medicine, College of Medicine, Seoul National University, Korea, 2012



- ✓ Doctor of Medicine, Dept. of Internal Medicine, College of Medicine, Seoul National University, Korea, 2020

Career/Employment

- ✓ Internship, Seoul National University Hospital Mar, 2002 ~ Feb, 2003
- ✓ Medical Officer, Republic of Korea Army Mar, 2003 ~ Apr. 2006
- ✓ Residency, Dept. of Internal Medicine, Seoul National University Hospital
May, 2006 ~ Feb, 2010
- ✓ Fellowship, Gastroenterology, Dept. of Internal Medicine, Seoul National University Hospital
Mar, 2010~Feb. 2012
- ✓ Assistant professor, Gastroenterology, Dept. of Internal Medicine, Kangwon National University Hospital
Mar, 2012~Jun. 2013
- ✓ Assistant professor, Gastroenterology, Dept. of Internal Medicine, Seoul National University Bundang Hospital
July. 2013~Aug. 2017
- ✓ Associate professor, Gastroenterology, Dept. of Internal Medicine, Seoul National University Bundang Hospital
Sep. 2017 ~ Feb. 2023
- ✓ Professor, Gastroenterology, Dept. of Internal Medicine, Seoul National University Bundang Hospital
Mar. 2023 ~
- ✓ Visiting Scholar
Nov, 2017 ~ Feb, 2019

Membership

- ✓ The Korean Society of Gastroenterology
- ✓ The Korean Society of Gastrointestinal Endoscopy
- ✓ The Korean Pancreatobiliary Association



- ✓ Society of Gastrointestinal Intervention
- ✓ Korean Society of Cancer Prevention
- ✓ Korean Society of Gastrointestinal Cancer Research

Board Member

- ✓ The Korean Society of Gastroenterology
 - Scientific Committee
- ✓ The Korean Pancreatobiliary Association
 - Pancreatic Study Group
- ✓ Korean Society of Cancer Prevention
 - Scientific Committee
- ✓ Korean Society of Gastrointestinal Cancer Research
 - Scientific Committee

Original Articles (English)

1. Jang ES, Lee DH, Kim J, et al. Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. *Hepatogastroenterology* 2009;56:1304-9.
2. Kim J, Choi IJ, Kim CG, et al. Self-expandable metallic stent placement for malignant obstruction in patients with locally recurrent gastric cancer. *Surg Endosc* 2011;25:1505-13.
3. Kim J, Lee WJ, Lee SH, et al. Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours. *Dig Liver Dis* 2011;43:965-70.
4. Kim J, Lee SH, Paik WH, et al. Clinical outcomes of patients who experienced perforation associated with endoscopic retrograde cholangiopancreatography. *Surg Endosc* 2012;26:3293-300.
5. Kim J, Ryu JK, Ahn DW, et al. Results of repeat endoscopic retrograde cholangiopancreatography after initial biliary cannulation failure following needle-knife



- sphincterotomy. *J Gastroenterol Hepatol* 2012;27:516-20.
6. Ahn DW, Lee SH, Kim J, et al. Long-term outcome of cystic lesions in the pancreas: a retrospective cohort study. *Gut Liver* 2012;6:493-500.
 7. Paik WH, Lee SH, Ryu JK, et al. Long-term clinical outcome of biliary cast syndrome in liver transplantation recipients. *Liver Transpl* 2012.
 8. Ahn DW, Ryu JK, Kim J, et al. Endoscopic papillectomy for benign ampullary neoplasms: how can treatment outcome be predicted? *Gut Liver* 2013;7:239-45.
 9. Ahn DW, Ryu JK, Kim J, et al. Inflexinol reduces severity of acute pancreatitis by inhibiting nuclear factor-kappaB activation in cerulein-induced pancreatitis. *Pancreas* 2013;42:279-84.
 10. Paik WH, Ryu JK, Song BJ, et al. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm. *J Korean Med Sci* 2013;28:750-4.
 11. Son JH, Kim J, Lee SH, et al. The optimal duration of preoperative biliary drainage for periampullary tumors that cause severe obstructive jaundice. *Am J Surg* 2013;206:40-6.
 12. Park JK, Paik WH, Ryu JK, et al. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. *PLoS One* 2013;8:e78977.
 13. Kim J, Ryu JK, Park JM, et al. Clinical factors associated with accuracy of EUS-FNA for pancreatic or peripancreatic solid mass without on-site cytopathologists. *J Gastroenterol Hepatol* 2014;29:887-92.
 14. Kim J, Ryu JK, Kim C, et al. Is there any role of positron emission tomography computed tomography for predicting resectability of gallbladder cancer? *J Korean Med Sci* 2014;29:680-4.
 15. Paik WH, Ryu JK, Park JM, et al. Which is the better treatment for the removal of large biliary stones? Endoscopic papillary large balloon dilation versus endoscopic sphincterotomy. *Gut Liver* 2014;8:438-44.
 16. Lee YS, Paik KH, Kim HW, et al. Comparison of Endoscopic Ultrasonography, Computed Tomography, and Magnetic Resonance Imaging for Pancreas Cystic Lesions. *Medicine (Baltimore)* 2015;94:e1666.
 17. Lee YS, Kang BK, Hwang IK, et al. Long-term Outcomes of Symptomatic Gallbladder Sludge. *J Clin Gastroenterol* 2015;49:594-8.
 18. Hwang IK, Lee YS, Kim J, et al. Do we really need additional contrast-enhanced abdominal computed tomography for differential diagnosis in triage of middle-aged subjects with suspected biliary pain. *Medicine (Baltimore)* 2015;94:e546.
 19. Kim J, Lee YS, Hwang IK, et al. Postoperative carcinoembryonic antigen as a complementary



- tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma. *J Korean Med Sci* 2015;30:259-63.
20. Yoon H, Lee DH, Jang ES, et al. Optimal initiation of *Helicobacter pylori* eradication in patients with peptic ulcer bleeding. *J Korean Med Sci* 2015;21:2497-503.
 21. Hwang IK, Kang BK, Lee YS, et al. Postoperative early thromboembolism as a prognostic indicator in patients with curatively resected pancreatic cancer. *Am J Surg* 2015;210:871-7.
 22. Kim HW, Lee JC, Paik KH, et al. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. *Medicine (Baltimore)* 2015;94:e1012.
 23. Hwang IK, Kim H, Lee YS, et al. The presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. *Cancer Sci* 2015.
 24. Kim GH, Chung JW, Lee JH, et al. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study. *Clin Mol Hepatol* 2015;21:379-86.
 25. Lee YS, Kim H, Kim HW, et al. High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor. *Medicine (Baltimore)* 2015;94:e2224.
 26. Park JK, Song BJ, Ryu JK, et al. Clinical Outcomes of Endoscopic Ultrasonography-Guided Pancreatic Cyst Ablation. *Pancreas* 2016;45:889-94.
 27. Lee JC, Ahn S, Paik KH, et al. Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol. *BMJ Open* 2016;6:e010491.
 28. Lee BS, Ryu JK, Jang DK, et al. Reintervention for occluded metal stent in malignant bile duct obstruction: A prospective randomized trial comparing covered and uncovered metal stent. *J Gastroenterol Hepatol* 2016;31:1901-1907.
 29. Paik KH, Lee JC, Kim HW, et al. Risk Factors for Gallstone Formation in Resected Gastric Cancer Patients. *Medicine (Baltimore)* 2016;95:e3157.
 30. Kim J, Ryu JK, Lee SH, et al. MicroRNA 141 Expression Is a Potential Prognostic Marker of Biliary Tract Cancers. *Gut Liver* 2016;10:836-41.
 31. Si WK, Chung JW, Cho J, et al. Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. *PLoS One* 2016;11:e0158066.
 32. Kang J, Paik KH, Lee JC, et al. The Efficacy of Clinical Predictors for Patients with Intermediate Risk of Cholelithiasis. *Digestion* 2016;94:100-105.
 33. Chung JW, Kim BH, Lee CS, et al. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. *PLoS One* 2016;11:e0168189.
 34. Choi JH, Kim HW, Lee JC, et al. Percutaneous transhepatic versus EUS-guided gallbladder drainage for malignant cystic duct obstruction. *Gastrointest Endosc* 2017;85:357-364.



35. Kim HW, Lee JC, Paik KH, et al. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. *Medicine (Baltimore)* 2017;96:e5926.
36. Kim HW, Lee JC, Paik KH, et al. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. *Surgery* 2017;161:1579-1587.
37. Kim HW, Lee JC, Lee J, et al. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. *PLoS One* 2017;12:e0173960.
38. Lee JC, Kim JW, Ahn S, et al. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. *Eur J Cancer* 2017;76:125-133.
39. Park H, Lee Y, Lee H, et al. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. *Tumour Biol* 2017;39:1010428317718403.
40. Lee Y, Lee H, Park H, et al. Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas. *Oncotarget* 2017;8:76699-76711.
41. Chung JW, Jang ES, Kim J, et al. Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. *Oncotarget* 2017;8:106499-106510.
42. Ahn DW, Lee SH, Paik WH, et al. Effects of Saline Irrigation of the Bile Duct to Reduce the Rate of Residual Common Bile Duct Stones: A Multicenter, Prospective, Randomized Study. *Am J Gastroenterol* 2018;113:548-555.
43. Lee JC, Ahn S, Cho IK, et al. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. *BMJ Open* 2018;8:e017249.
44. Lee JC, Kim H, Kim HW, et al. It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. *Hepatobiliary Pancreat Dis Int* 2018;17:553-558.
45. Lee JC, Kim JS, Kim HW, et al. Outcome of endoscopic retrograde cholangiopancreatography in patients with clinically defined decompensated liver cirrhosis. *J Dig Dis* 2018;19:605-613.
46. Lee CH, Yoon H, Choi YJ, et al. Predictive factors of therapeutic intervention in on-call endoscopy for suspected gastrointestinal bleeding. *Scand J Gastroenterol* 2018;53:958-963.
47. Jo JH, Cho CM, Jun JH, et al. Same-session endoscopic ultrasound-guided fine needle aspiration and endoscopic retrograde cholangiopancreatography-based tissue sampling in suspected malignant biliary obstruction: A multicenter experience. *J Gastroenterol Hepatol* 2018.
48. Kim J, Kim H, Lee JC, et al. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. *PLoS One* 2018;13:e0209104.



49. Lee J, Lee JC, Gromski MA, et al. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. *Medicine (Baltimore)* 2018;97:e13592.
50. Shin DW, Lee JC, Kim J, et al. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. *Eur J Surg Oncol* 2019;45:2159-2165.
51. Lee YS, Lee JC, Yang SY, et al. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. *Sci Rep* 2019;9:15662.
52. Cho E, Park CH, Kim TH, et al. A prospective, randomized, multicenter clinical trial comparing 25-gauge and 20-gauge biopsy needles for endoscopic ultrasound-guided sampling of solid pancreatic lesions. *Surg Endosc* 2020;34:1310-1317.
53. Cho IK, Kim H, Lee JC, et al. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. *Gut Liver* 2020;14:521-528.
54. Park JM, Kang CD, Lee JC, et al. Recent 5-Year Trend of Endoscopic Retrograde Cholangiography in Korea Using National Health Insurance Review and Assessment Service Open Data. *Gut Liver* 2020;14:833-841.
55. Kim J, Braun D, Ukaegbu C, et al. Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome. *Clin Gastroenterol Hepatol* 2020;18:830-837.e1.
56. Lee JC, Shin DW, Park H, et al. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. *Gastrointest Endosc* 2020;92:1044-1052.e1.
57. Shin DW, Kim MJ, Lee JC, et al. Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma: A Large Multicenter Study. *Am J Clin Oncol* 2020;43:422-427.
58. Ahn S, Lee JC, Shin DW, et al. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. *Sci Rep* 2020;10:12348.
59. Cho JH, Yoon YS, Kim EJ, et al. A multicenter prospective randomized controlled trial for preoperative biliary drainage with uncovered metal versus plastic stents for resectable periampullary cancer. *J Hepatobiliary Pancreat Sci* 2020;27:690-699.
60. Chung KH, Lee JC, Lee J, et al. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. *Pancreatol* 2020;20:1465-1471.
61. Lee JC, Woo SM, Shin DW, et al. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. *Am J Clin Oncol* 2020;43:654-659.
62. Kim JH, Youn Y, Lee JC, et al. Involvement of the NF- κ B signaling pathway in proliferation



- and invasion inhibited by Zwint-1 deficiency in Pancreatic Cancer Cells. *J Cancer* 2020;11:5601-5611.
63. Lee J, Lee JC, Kim HW, et al. Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer. *PLoS One* 2020;15:e0238649.
 64. Youn Y, Lee JC, Kim J, et al. Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells. *Sci Rep* 2020;10:16518.
 65. Jung JH, Shin DW, Kim J, et al. Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment. *Cancers (Basel)* 2020;12.
 66. Song DH, Cho IK, Shin DW, et al. The clinical significance of preoperative C-reactive protein/albumin ratio in patients with resected extrahepatic bile duct cancer. *Surg Today* 2021;51:978-985.
 67. Kim J, Ji E, Jung K, et al. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. *J Pers Med* 2021;11.
 68. Kim J. Gastrointestinal Bleeding Of Unknown Origin In Patients With Splenic Aneurysm. *Clin Endosc* 2021;54:293-294.
 69. Shin DW, Lee JC, Kim J, et al. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. *Pancreatology* 2021;21:796-804.
 70. Ahn S, Lee JC, Kim J, et al. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy. *Gut Liver* 2022;16:129-137.
 71. Shin DW, Kim MA, Lee JC, et al. Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. *BMC Res Notes* 2021;14:272.
 72. Lee HK, Yoon YS, Han HS, et al. Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer. *Cancers (Basel)* 2021;13.
 73. Lee YS, Lee JC, Kim JH, et al. Pharmacoefficacy of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. *Sci Rep* 2021;11:20152.
 74. Jung K, Park J, Jung JH, et al. Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis. *Gut Liver* 2022;16:798-805.
 75. Kim HY, Lee YJ, Chang W, et al. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study. *Eur Radiol* 2022;32:3799-3807.



76. Ju Kim Y, Jin Yoon C, Hwan Lee J, et al. Transhepatic stent placement for malignant portal vein obstruction: Long term efficacy and factors associated with stent failure. *Eur J Radiol* 2022;149:110230.
77. Kim B, Park J, Ahn J, et al. Prediction model using clinical factors for radiation exposure during endoscopic retrograde cholangiopancreatography. *J Gastroenterol Hepatol* 2022;37:1342-1348.
78. Shin DW, Park J, Lee JC, et al. Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. *Cancers (Basel)* 2022;14.
79. Kim JH, Youn Y, Lee JC, et al. Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. *Cancer Biomark* 2022;34:647-659.
80. Ahn J, Ahn DW, Park J, et al. Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer. *J Gastrointest Oncol* 2022;13:1981-1988.
81. Jung K, Lee S, Na HY, et al. NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. *Sci Rep* 2022;12:20937.
82. Lee JC, Lee BJ, Park C, et al. Efficacy improvement in searching MEDLINE database using a novel PubMed visual analytic system: EEEvis. *PLoS One* 2023;18:e0281422.
83. Jung JH, Song C, Jung IH, et al. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. *Front Oncol* 2022;12:1050070.
84. Yang MJ, Kim J, Park SW, et al. Comparison between three types of needles for endoscopic ultrasound-guided tissue acquisition of pancreatic solid masses: a multicenter observational study. *Sci Rep* 2023;13:3677.
85. Shin DW, Kim S, Jung K, et al. Impact of histopathological type on the prognosis of ampullary carcinoma: A systematic review and meta-analysis. *Eur J Surg Oncol* 2023;49:306-315.
86. Cho JH, Kim J, Lee HS, et al. Factors Influencing the Diagnostic Performance of Repeat Endoscopic Ultrasound-Guided Fine-Needle Aspiration/Biopsy after the First Inconclusive Diagnosis of Pancreatic Solid Lesions. *Gut Liver* 2023.
87. Park J, Park J, Lee YS, et al. Increased incidence of indeterminate pancreatic cysts and changes of management pattern: Evidence from nationwide data. *Hepatobiliary Pancreat Dis Int* 2023;22:294-301.
88. Jung K, Choi S, Song H, et al. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. *Ther Adv Med Oncol* 2023;15:17588359231175441.
89. Park J, Kim HY, Na HY, et al. Continued adjuvant FOLFIRINOX for BRPC or LAPC after



- neoadjuvant FOLFIRINOX. *J Cancer Res Clin Oncol* 2023;149:1765-1775.
90. Jung JH, Won SH, Jung K, et al. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. *Gut Liver* 2023.
 91. Cho JH, Kim J, Lee HS, et al. Factors Influencing the Diagnostic Performance of Repeat Endoscopic Ultrasound-Guided Fine-Needle Aspiration/Biopsy after the First Inconclusive Diagnosis of Pancreatic Solid Lesions. *Gut Liver* 2024;18:184-191.
 92. Jung JH, Won SH, Jung K, et al. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. *Gut Liver* 2024;18:737-746.
 93. Kim KY, Yoon CJ, Lee JH, et al. Percutaneous endobiliary radiofrequency ablation with stent placement in type IV hilar cholangiocarcinoma: A prospective comparison with stent placement alone. *Eur J Radiol* 2024;176:111516.
 94. Kim MK, Cho IR, Kim Y, et al. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. *Ther Adv Med Oncol* 2024;16:17588359241290482.
 95. Yoon SB, Woo SM, Chun JW, et al. The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis. *Front Immunol* 2024;15:1321813.
 96. Ahn J, Song YS, Kim B, et al. Prognostic Value of the Metabolic Response on Serial (18)F-FDG PET/CT in Pancreatic Cancer. *Gut Liver* 2025;19:462-472.
 97. Hong S, Kim J, Chung G, et al. Revolutionizing drug delivery: low-intensity pulsed ultrasound (LIPUS)-driven deep penetration into hypoxic tumor microenvironments of cholangiocarcinoma. *Theranostics* 2025;15:30-51.
 98. Kim B, Kim J, Yang S, et al. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. *World J Gastrointest Oncol* 2025;17:100167.
 99. Kim B, Park J, Na HY, et al. The origin of patient-derived cancer organoids from pathologically undiagnosed specimen in patients with pancreatobiliary cancers. *Cell Oncol (Dordr)* 2025;48:523-535.
 100. Kim J, Lee YS, Lee JC, et al. Choledocholithiasis as a risk factor for cholangiocarcinoma: a nationwide retrospective cohort study. *BMC Gastroenterol* 2025;25:138.
 101. Kim JW, Na HY, Lee S, et al. Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital. *Sci Rep* 2025;15:2171.
 102. Lee JC, Kang SW, Sim EJ, et al. Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer. *BMC Cancer* 2025;25:762.

Seoul International Digestive Disease Symposium 2026

SIDDS 2026



Date Apr. 18.(Sat)-19.(Sun) 2026

Venue Grand Walkerhill Seoul, Korea

Navigating Towards the Optimum Digestive Care : Beyond Linguistic Barriers

103. Lee TS, Choi JH, Lee JM, et al. A randomized non-inferiority trial investigating antibiotic adjustments based on blood culture in acute cholangitis. *Clin Microbiol Infect* 2025;31:987-994.
104. Oh S, Kim J, Shin CM, et al. Metagenomic characterization of oral microbiome signatures to predict upper gastrointestinal and pancreaticobiliary cancers: a case-control study. *J Transl Med* 2025;23:20.

